Cargando…

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”

Detalles Bibliográficos
Autor principal:	Kaya, Abdullah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841436/ https://www.ncbi.nlm.nih.gov/pubmed/27143846 http://dx.doi.org/10.2147/OPTH.S108314

Ejemplares similares

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
por: Razi, Faraz, et al.
Publicado: (2016)

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
por: Zhang, Xinyuan, et al.
Publicado: (2018)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
por: Gungel, Hulya, et al.
Publicado: (2014)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections
por: Calvo, Pilar, et al.
Publicado: (2015)

Effect of Phacoemulsification on Visual Acuity and Macular Morphology in Patients with Wet Age-Related Macular Degeneration
por: Figurska, Małgorzata, et al.
Publicado: (2018)

Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration
por: Williams, Gwyn Samuel, et al.
Publicado: (2015)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity
por: Feigl, Beatrix, et al.
Publicado: (2007)

Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
por: Mulyukov, Zufar, et al.
Publicado: (2018)

Functional Visual Acuity in Age-Related Macular Degeneration
por: Tomita, Yohei, et al.
Publicado: (2016)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study
por: Oshima, Yuji, et al.
Publicado: (2021)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Lu, Yan, et al.
Publicado: (2021)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
por: Lu, Yingyi, et al.
Publicado: (2016)

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017)

Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
por: El Matri, Leila, et al.
Publicado: (2012)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020)

Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
por: Minami, Sakiko, et al.
Publicado: (2018)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion
por: Lloyd Clark, W., et al.
Publicado: (2019)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration
por: Chen, Ling, et al.
Publicado: (2020)

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure
por: Liu, Haiyang, et al.
Publicado: (2018)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Sül, Sabahattin, et al.
Publicado: (2019)

Mental health and visual acuity in patients with age-related macular degeneration
por: Fonteh, Cheryl N., et al.
Publicado: (2022)

Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration
por: Lee, Sangmoon, et al.
Publicado: (2013)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
por: Joshi, Shrinivas, et al.
Publicado: (2023)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration
por: Fu, Haojie, et al.
Publicado: (2017)

Relevance of Visual Acuity Measurement for Therapeutic Decisions in Age-Related Macular Degeneration
por: Mathis, Thibaud, et al.
Publicado: (2023)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity
por: Mori, Ryusaburo, et al.
Publicado: (2018)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
por: Sabour-Pickett, Sarah, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_upfchm0aoimptf882uo6le9qbl